Maddrey's Discriminant Function
Is alcohol-associated hepatitis severe enough to consider corticosteroids?
Calculator
Fields marked * are required. Units can be changed per field.
Result
Your result will appear here
Complete the inputs and select Calculate. Results update instantly for point scores.
About this tool
Prognostic index from prothrombin time and bilirubin in alcohol-associated hepatitis.
Intended use
Patients with clinically diagnosed alcohol-associated hepatitis.
Outcome
Short-term mortality
Time horizon
~30 days
Derivation population
Patients with alcoholic hepatitis in a corticosteroid trial.
Limitations
- PT varies by reagent.
- MELD and Lille models are commonly used alongside.
Clinical problems
Evidence
Evidence level
Moderate evidence
Externally validated, or an established physiological equation whose clinical thresholds rest on consensus; guideline support limited or mixed. Methodology
References
- Original publicationMaddrey WC, Boitnott JK, Bedine MS, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978;75:193-199. Find on PubMed (opens in a new tab)
Version history
| Version | Formula | Effective | Reviewer | Changes |
|---|---|---|---|---|
| v1.0.0 | Maddrey 1978 (modified, 4.6 coefficient) | 2026-10-03 | — | Initial implementation with reference test vectors. |
Related tools
APRI
Is significant fibrosis or cirrhosis likely in chronic hepatitis?
Hepatology · Risk scoreChild-Pugh
How severe is this patient's cirrhosis?
Hepatology · EquationFIB-4
Does this patient likely have advanced liver fibrosis?
Hepatology · EquationMELD 3.0
What is the 90-day wait-list mortality risk in end-stage liver disease?
Clinical decision support only. Interpret results in the context of the individual patient and current guidance; HumanPulse does not replace professional medical judgment.